Magna gibt Ergebnisse der Jahreshauptversammlung 2024 bekannt
AURORA, Ontario, May 13, 2024 (GLOBE NEWSWIRE) — Magna gibt Ergebnisse der Jahreshauptversammlung 2024 bekannt AURORA, Ontario, 9. Mai 2024 […]
Magna lève le voile sur les résultats de son assemblée générale 2024
AURORA, Province de l’Ontario, 13 mai 2024 (GLOBE NEWSWIRE) — Magna International, Inc. (TSX : MG ; NYSE : MGA) publie les résultats du scrutin […]
TRANSFORMA ANNOUNCES FAILURE TO FILE CEASE TRADE ORDER
Not for distribution to United States newswire services or for dissemination in the United States. Vancouver, May 13, 2024 (GLOBE […]
GOGL – Invitation to presentation of Q1 2024 Results
Golden Ocean Group Limited (the “Company) will publish its financial results for the first quarter of 2024 on Wednesday May […]
NVIDIA Accelerates Quantum Computing Centers Worldwide With CUDA-Q Platform
HAMBURG, Germany, May 12, 2024 (GLOBE NEWSWIRE) — ISC — NVIDIA today announced that it will accelerate quantum computing efforts […]
NVIDIA Grace Hopper Ignites New Era of AI Supercomputing
HAMBURG, Germany, May 12, 2024 (GLOBE NEWSWIRE) — ISC—Driving a fundamental shift in the high-performance computing industry toward AI-powered systems, […]
Caledonia Mining Corporation Plc Results for the Quarter ended March 31, 2024; Notice of Management Conference Call
ST HELIER, Jersey, May 13, 2024 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or “the Company”) (NYSE AMERICAN: CMCL; AIM: […]
QIAGEN erhält FDA-Zulassung für syndromischen QIAstat-Dx-Test zur schnellen und präzisen Diagnose von Atemwegserkrankungen
GERMANTOWN, Md. und VENLO, Niederlande, May 13, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurter Prime Standard: QIA) hat heute […]
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results
Germantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today […]
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled […]
